Ingrid Karlsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ingrid Karlsson has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Björn Frendéus
BioInvent International AB, Lund, Sweden
28 shared publications - Ingrid Teige
BioInvent International AB, Lund, Sweden
28 shared publications - Linda Mårtensson
BioInvent International AB, Lund, Sweden
28 shared publications - Andres McAllister
BioInvent International AB, Lund, Sweden
15 shared publications - Danijela Lindahl
BioInvent International AB, Lund, Sweden
15 shared publications - Johan Wallin
BioInvent International AB, Lund, Sweden
15 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF20
Anti-TNFR2 Antibody BI-1808 Induces Tumor Regression and Antitumor T-cell Immunity through Treg and Myeloid Cell Modulation in Patients with Solid Tumors
Purpose: The aim of the study is to clinically evaluate the safety, pharmacodynamic (PD) biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor (FcγR)–engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in patients with solid cancer. Patients and Methods: Preclinical modeling in syngeneic tumor models was used to assess the relationship between dose, pharmacokinetics (PK), receptor occupancy (RO), and efficacy, as well as PD biomarkers measured in peripheral blood and tumors. These findings informed dosing and analyses in a first-in-human phase I dose-escalation trial in patients with solid cancers. Results: BI-1808 was safe and well tolerated, showed expected PK, and achieved full RO throughout the 3-week dosing interval. Tumor regression was observed in two patients, one with non–small cell lung cancer and one with gastrointestinal sarcoma. Stable disease was observed in 6 of 21 evaluable patients. Tumor regression was preceded by increases in circulating CX3CR1+CD8+ T cells and tumor-infiltrating CD8+ T cells, consistent with the activation of antitumor immunity. PD analyses were consistent with the preclinically characterized mechanism of action, including dose-dependent reduction of regulatory T cells, monocyte activation, and serum cytokines indicating myeloid reprogramming, tertiary lymphoid structure formation, and CD8+ T-cell activation. Conclusions: These early clinical findings support further development of ligand-blocking, FcγR-engaging anti-TNFR2 antibodies as a safe and mechanistically distinct cancer immunotherapy strategy. The excellent safety profile of BI-1808 makes it well-suited for combination with other immunotherapies, targeted agents, chemotherapeutics, cell therapies, and antibody–drug conjugates.
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF20
Open AccessAnti-TNFR2 Antibody BI-1808 Induces Tumor Regression and Antitumor T-cell Immunity through Treg and Myeloid Cell Modulation in Patients with Solid Tumors
Purpose: The aim of the study is to clinically evaluate the safety, pharmacodynamic (PD) biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor (FcγR)–engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in patients with solid cancer. Patients and Methods: Preclinical modeling in syngeneic tumor models was used to assess the relationship between dose, pharmacokinetics (PK), receptor occupancy (RO), and efficacy, as well as PD biomarkers measured in peripheral blood and tumors. These findings informed dosing and analyses in a first-in-human phase I dose-escalation trial in patients with solid cancers. Results: BI-1808 was safe and well tolerated, showed expected PK, and achieved full RO throughout the 3-week dosing interval. Tumor regression was observed in two patients, one with non–small cell lung cancer and one with gastrointestinal sarcoma. Stable disease was observed in 6 of 21 evaluable patients. Tumor regression was preceded by increases in circulating CX3CR1+CD8+ T cells and tumor-infiltrating CD8+ T cells, consistent with the activation of antitumor immunity. PD analyses were consistent with the preclinically characterized mechanism of action, including dose-dependent reduction of regulatory T cells, monocyte activation, and serum cytokines indicating myeloid reprogramming, tertiary lymphoid structure formation, and CD8+ T-cell activation. Conclusions: These early clinical findings support further development of ligand-blocking, FcγR-engaging anti-TNFR2 antibodies as a safe and mechanistically distinct cancer immunotherapy strategy. The excellent safety profile of BI-1808 makes it well-suited for combination with other immunotherapies, targeted agents, chemotherapeutics, cell therapies, and antibody–drug conjugates.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Generated antibodies are TNFR2 specific and act as functional agonists or blockers
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 1 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Generated antibodies are TNFR2 specific and act as functional agonists or blockers
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
TNFR2 / TNFR1 ratios, CT26 tumor-bearing mice
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 10 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
TNFR2 / TNFR1 ratios, CT26 tumor-bearing mice
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Immune cell infiltration in CT26, MC38 and EMT6 mouse models.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 2 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Immune cell infiltration in CT26, MC38 and EMT6 mouse models.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Anti-tumor effect is long-lived and independent of tumor TNFR2 or TNFR1 expression
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 3 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Anti-tumor effect is long-lived and independent of tumor TNFR2 or TNFR1 expression
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Both types of α-TNFR2 antibodies have broad anti-tumor effect and synergize with α-PD1
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 4 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Both types of α-TNFR2 antibodies have broad anti-tumor effect and synergize with α-PD1
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Ligand-blocking 3F10 and agonist 5A05 bind independently of each other and the inhibiton of anti-tumor effects is dependent on factors beyond FcγR competition
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 5 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Ligand-blocking 3F10 and agonist 5A05 bind independently of each other and the inhibiton of anti-tumor effects is dependent on factors beyond FcγR competition
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 6 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Characterization of transcriptionally distinct cell populations following antibody treatments.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 6 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Characterization of transcriptionally distinct cell populations following antibody treatments.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Flow cytometry histograms for myeloid sub-population identification
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 7 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Flow cytometry histograms for myeloid sub-population identification
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity
Supplementary Fig 8 from Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity